Crick-Cancer Research UK and Crick doctoral fellowships for clinicians

Scientists 2

Applications for Crick-Cancer Research UK (Crick-CRUK) and Crick doctoral fellowships for clinicians to start in September 2018 are now closed. Interviews will be held on Tuesday 6 February 2018.

Crick-CRUK and Crick doctoral fellowships for clinicians provide an opportunity for exceptional clinicians to gain a broad and deep interdisciplinary research experience while performing innovative biomedical discovery research. Fellows carry out exciting research projects for three years while following the Crick's clinical PhD programme.

The Crick is a brand new institute with exceptional state-of-the-art science technology platforms that all Crick scientists can access. The Crick's research is dedicated to understanding the scientific mechanisms of living organisms, helping us to understand why disease develops and to find new ways to prevent, diagnose and treat illnesses.

A key aim of the Crick is to advance the understanding of cancer at the most fundamental level and to speed application of this knowledge for therapeutic and diagnostic patient benefit. The Crick-CRUK fellowships are funded by an Accelerator Award from Cancer Research UK.

These fellowships bring together scientists and clinicians from the Crick and five clinical PhD programme partners: Barts Cancer Institute/Queen Mary University of London (BCI/QMUL), Imperial College London, The Institute of Cancer Research (ICR), King's College London and UCL. Fellows on the programme are based at the Crick, supervised by a primary supervisor from the Crick, together with a secondary supervisor from one of the programme partners and a practicing clinician who acts as a training mentor during the programme.

For further information see:

  • "Clinical training in specialties allied to oncology is increasingly dependent on the ability to critically appraise evidence and understand complex biological and genetic processes. The clinical PhD programme at the Crick provides an unprecedented opportunity to conduct biomedical research in areas such as tumour immunology and the microenvironment, cancer functional genomics and evolution, infectious disease and neuroscience."                 Charles Swanton, Translational Cancer Therapeutics group leader